IRIS Accounts Production v25.1.0.734 00905546 Board of Directors 1.1.24 31.12.24 31.12.24 8.4.25 0 0 false true false false true false Auditors Opinion iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh009055462023-12-31009055462024-12-31009055462024-01-012024-12-31009055462023-06-30009055462023-07-012023-12-31009055462023-12-3100905546ns15:EnglandWales2024-01-012024-12-3100905546ns14:PoundSterling2024-01-012024-12-3100905546ns10:Director12024-01-012024-12-3100905546ns10:PrivateLimitedCompanyLtd2024-01-012024-12-3100905546ns10:SmallEntities2024-01-012024-12-3100905546ns10:Audited2024-01-012024-12-3100905546ns10:SmallCompaniesRegimeForDirectorsReport2024-01-012024-12-3100905546ns10:SmallCompaniesRegimeForAccounts2024-01-012024-12-3100905546ns10:FullAccounts2024-01-012024-12-3100905546ns10:Director22024-01-012024-12-3100905546ns10:RegisteredOffice2024-01-012024-12-3100905546ns5:CurrentFinancialInstruments2024-12-3100905546ns5:CurrentFinancialInstruments2023-12-3100905546ns5:ShareCapital2024-12-3100905546ns5:ShareCapital2023-12-3100905546ns5:SharePremium2024-12-3100905546ns5:SharePremium2023-12-3100905546ns5:FurtherSpecificReserve1ComponentTotalEquity2024-12-3100905546ns5:FurtherSpecificReserve1ComponentTotalEquity2023-12-3100905546ns5:RetainedEarningsAccumulatedLosses2024-12-3100905546ns5:RetainedEarningsAccumulatedLosses2023-12-3100905546ns5:WithinOneYearns5:CurrentFinancialInstruments2024-12-3100905546ns5:WithinOneYearns5:CurrentFinancialInstruments2023-12-31
REGISTERED NUMBER: 00905546 (England and Wales)



































Financial Statements

for the Year Ended 31 December 2024

for

STD Pharmaceutical Products Limited

STD Pharmaceutical Products Limited (Registered number: 00905546)






Contents of the Financial Statements
for the Year Ended 31 December 2024




Page

Company Information 1

Statement of Financial Position 2

Notes to the Financial Statements 3


STD Pharmaceutical Products Limited

Company Information
for the Year Ended 31 December 2024







DIRECTORS: B.M. Gardiner
Dr S C Travers





REGISTERED OFFICE: Plough Lane
Hereford
HR4 OEL





REGISTERED NUMBER: 00905546 (England and Wales)





AUDITORS: Thorne Widgery Accountancy Ltd
Chartered Accountants
Statutory Auditors
2 Wyevale Business Park
Kings Acre
Hereford
Herefordshire
HR4 7BS

STD Pharmaceutical Products Limited (Registered number: 00905546)

Statement of Financial Position
31 December 2024

31.12.24 31.12.23
Notes £    £   
CURRENT ASSETS
Stocks 715,329 678,274
Debtors 4 474,345 473,305
Cash at bank 1,030,275 427,535
2,219,949 1,579,114
CREDITORS
Amounts falling due within one year 5 (355,841 ) (472,899 )
NET CURRENT ASSETS 1,864,108 1,106,215
TOTAL ASSETS LESS CURRENT LIABILITIES 1,864,108 1,106,215

CAPITAL AND RESERVES
Called up share capital 1,039 1,039
Share premium 1,900 1,900
Capital Contribution 550,977 550,977
Retained earnings 1,310,192 552,299
SHAREHOLDERS' FUNDS 1,864,108 1,106,215

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 1 April 2025 and were signed on its behalf by:





Dr S C Travers - Director


STD Pharmaceutical Products Limited (Registered number: 00905546)

Notes to the Financial Statements
for the Year Ended 31 December 2024

1. STATUTORY INFORMATION

STD Pharmaceutical Products Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Going Concern
The directors have considered the basis on which the financial statements have been prepared, and are confident that the going-concern basis is appropriate for the following reasons:

The company is transitioning to a predominantly selling organisation responsible for distributing the Fibrovein range of products to customers in the UK. It has no premises, no staff and only limited overheads. Its selling and administrative processes are contracted out to a specialist company in the pharmaceutical sector. It remains responsible for protecting its pharmaceutical licences worldwide.

The company has cash in the bank at the end of December 2024 of £1,030,275 at prevailing exchange rates.

On 31st December there were sales ledger balances of approximately £446,133 again at prevailing exchange rates. The company also has a stocks balance of approximately £715,329 as shown in the financial statements.

The company retains the support of its parent company Chemische Fabrik Kreussler & Co. GmbH.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Net realisable value is based on estimated selling price less further costs to completion and disposal.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the statement of financial position date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

STD Pharmaceutical Products Limited (Registered number: 00905546)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2024

2. ACCOUNTING POLICIES - continued

Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the statement of financial position date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was NIL (2023 - NIL).

4. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.12.24 31.12.23
£    £   
Trade debtors 446,133 453,208
Other debtors 28,212 20,097
474,345 473,305

5. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.12.24 31.12.23
£    £   
Trade creditors 178,146 145,562
Taxation and social security 12,842 6,595
Other creditors 164,853 320,742
355,841 472,899

6. DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

The Report of the Auditors was unqualified.

Kevin Tong FCCA ACA (Senior Statutory Auditor)
for and on behalf of Thorne Widgery Accountancy Ltd

7. RELATED PARTY DISCLOSURES

The company is a wholly owned subsidiary of Fibrovein Holdings Limited. Its ultimate parent company is Chemische Fabrik Kreussler & Co. GmbH (Kreussler).

Management charges of £Nil (31st December 2023: £130,002) were paid to a company controlled by a Director during the year.

The company has made sales of £281,449 (31st December 2023: £Nil) to, and purchases of £228,653 (31st December 2023: £Nil) from Kreussler. On 31st December 2024, the company owed Kreussler £167,547 (31st December 2023: £Nil) and was owed £228,877 (31st December 2023: £Nil) by Kreussler.